###begin article-title 0
Elevated levels of placental growth factor represent an adaptive host response in sepsis
###end article-title 0
###begin p 1
###xml 32 55 32 55 <email xmlns:xlink="http://www.w3.org/1999/xlink">waird@bidmc.harvard.edu</email>
CORRESPONDENCE William C. Aird: waird@bidmc.harvard.edu
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 282 294 282 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">J. Exp. Med.</italic>
###xml 484 489 <span type="species:ncbi:10090">mouse</span>
###xml 1157 1161 <span type="species:ncbi:10090">mice</span>
Recently, we demonstrated that circulating levels of vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) are increased in sepsis (Yano, K., P.C. Liaw, J.M. Mullington, S.C. Shih, H. Okada, N. Bodyak, P.M. Kang, L. Toltl, B. Belikoff, J. Buras, et al. 2006. J. Exp. Med. 203:1447-1458). Moreover, enhanced VEGF/Flk-1 signaling was shown to contribute to sepsis morbidity and mortality. We tested the hypothesis that PlGF also contributes to sepsis outcome. In mouse models of endotoxemia and cecal ligation puncture, the genetic absence of PlGF or the systemic administration of neutralizing anti-PlGF antibodies resulted in higher mortality compared with wild-type or immunoglobulin G-injected controls, respectively. The increased mortality associated with genetic deficiency of PlGF was reversed by adenovirus (Ad)-mediated overexpression of PlGF. In the endotoxemia model, PlGF deficiency was associated with elevated circulating levels of VEGF, induction of VEGF expression in the liver, impaired cardiac function, and organ-specific accentuation of barrier dysfunction and inflammation. Mortality of endotoxemic PlGF-deficient mice was increased by Ad-mediated overexpression of VEGF and was blocked by expression of soluble Flt-1. Collectively, these data suggest that up-regulation of PlGF in sepsis is an adaptive host response that exerts its benefit, at least in part, by attenuating VEGF signaling.
###end p 3
###begin p 4
Abbreviations used: Ad, adenovirus; CLP, cecal ligation puncture; COX, cyclooxygenase; ICAM, intercellular adhesion molecule; MPO, myeloperoxidase; PlGF, placental growth factor; sFlt-1, soluble Flt-1; VCAM, vascular cell adhesion molecule; VEGF, vascular endothelial growth factor.
###end p 4
###begin p 5
###xml 207 208 207 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 353 354 353 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 460 461 460 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 601 602 601 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 603 604 603 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 701 702 701 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 703 705 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 855 856 855 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 858 860 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 677 682 <span type="species:ncbi:9606">human</span>
###xml 849 853 <span type="species:ncbi:10090">mice</span>
Vascular endothelial growth factor (VEGF; also termed VEGF-A) is a member of a growing family of related proteins that include VEGF-B, -C, and -D, and placental growth factor (PlGF; for review see reference 1). VEGF/vascular permeability factor was first identified and characterized by Senger et al. as a potent stimulator of endothelial permeability (2). VEGF was subsequently reported to promote proliferation, migration, and survival of endothelial cells (3). In addition, VEGF has been implicated in inflammatory processes, including rheumatoid arthritis, cancer, and inflammatory bowel disease (4-6). Several studies have demonstrated increased VEGF levels in animal and human models of sepsis (7-11). Importantly, inhibition of VEGF signaling with soluble Flt-1 (sFlt-1) or antibodies against Flk-1 improved morbidity and mortality in septic mice (7, 11).
###end p 5
###begin p 6
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 508 510 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 511 513 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 558 560 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 671 672 671 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 741 743 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 745 747 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 749 751 749 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 752 754 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 32 38 <span type="species:ncbi:9606">humans</span>
###xml 73 77 <span type="species:ncbi:10090">mice</span>
###xml 637 642 <span type="species:ncbi:10090">mouse</span>
###xml 647 652 <span type="species:ncbi:9606">human</span>
PlGF occurs in four isoforms in humans (PlGF-1-4), and in one isoform in mice (PlGF-2) (12-15). PlGF was originally identified in the placenta (13, 16) but has subsequently been shown to be expressed in other tissues, including the heart, lung, thyroid gland, and skeletal muscle (for review see reference 17). Circulating levels of PlGF are normally undetectable. However, increased PlGF levels have been described in several conditions, including cancer (18-20), cutaneous wound and bone fracture healing (21-24), atherosclerosis, and sickle cell disease (25). Recently, we demonstrated that circulating levels of PlGF are elevated in mouse and human models of sepsis (7). Previous studies have implicated a role for PlGF in inflammation (21, 23, 25-31). Thus, we hypothesized that elevated levels of PlGF in sepsis might contribute (as do increased VEGF levels) to the pathophysiology of the host response to infection. On the contrary, we found that PlGF protects against sepsis morbidity and mortality.
###end p 6
###begin title 7
RESULTS
###end title 7
###begin title 8
PlGF protein and mRNA levels are induced in animal models of sepsis
###end title 8
###begin p 9
###xml 149 150 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 161 164 161 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
###xml 523 531 523 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 623 631 623 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 788 789 788 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 1041 1049 1041 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 1176 1184 1176 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
###xml 356 360 <span type="species:ncbi:10090">mice</span>
We recently demonstrated that circulating PlGF levels are increased in C57BL/6 mice injected with LPS or subjected to cecal ligation puncture (CLP) (7). The PlGF-/- mice used in this study were backcrossed to an FVB background. Previous studies have demonstrated strain-specific sensitivity to LPS (32-34). Thus, we wished to confirm these findings in FVB mice. The i.p. administration of 18 mg/kg LPS resulted in a time-dependent increase in plasma PlGF concentrations, with peak levels (3,447.4 pg/ml) occurring at 24 h (Fig. 1 A). Similarly, in a CLP model of sepsis, peak levels of PlGF (111.4 pg/ml) occurred at 24 h (Fig. 1 A). Previously, we demonstrated that PlGF protein levels were increased in all tissues examined, including the brain, lung, heart, liver, kidney, and spleen (7). In real-time PCR assays, there was a time-dependent induction of PlGF transcripts at 24 h in the brain (5.3-fold), lung (14.3-fold), liver (28-fold), kidney (25.7-fold), and spleen (8.5-fold). PlGF mRNA levels in the heart peaked at 6 h (54.2-fold; Fig. 1 B). In situ hybridization and immunohistochemical studies revealed a PlGF signal in perivascular cells but not the endothelium (Fig. 1 C shows the heart, lung, and liver). Collectively, these findings suggest that sepsis is associated with the widespread induction of PlGF mRNA and protein expression.
###end p 9
###begin p 10
###xml 0 66 0 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink">PlGF levels in sepsis and survival studies in PlGF-deficient mice.</bold>
###xml 309 310 309 310 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 809 812 807 810 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 836 839 834 837 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 928 931 926 929 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 944 947 942 945 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1166 1169 1164 1167 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1182 1185 1180 1183 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1249 1252 1247 1250 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1265 1268 1263 1266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 61 65 <span type="species:ncbi:10090">mice</span>
###xml 118 122 <span type="species:ncbi:10090">mice</span>
###xml 215 220 <span type="species:ncbi:10090">mouse</span>
###xml 358 362 <span type="species:ncbi:10090">mice</span>
###xml 540 544 <span type="species:ncbi:10090">mice</span>
###xml 855 859 <span type="species:ncbi:10090">mice</span>
###xml 953 957 <span type="species:ncbi:10090">mice</span>
###xml 1030 1034 <span type="species:ncbi:10090">mice</span>
###xml 1191 1195 <span type="species:ncbi:10090">mice</span>
###xml 1274 1278 <span type="species:ncbi:10090">mice</span>
###xml 1336 1340 <span type="species:ncbi:10090">mice</span>
PlGF levels in sepsis and survival studies in PlGF-deficient mice. (A, a) Plasma levels of PlGF in wild-type male FVB mice injected i.p. with 18 mg/kg LPS at the time points indicated. (b) Same as in a but in a CLP mouse model. (B) Shown are results of quantitative real-time analyses (mRNA copy number per 106 copies of 18S) of PlGF in organs from male FVB mice at various time points after i.p. injection with 18 mg/kg LPS. (C) In situ hybridization (ISH) and immunohistochemistry (IHC) for PlGF in the heart, lung, and liver of male FVB mice treated in the absence (nontreated) or presence of 18 mg/kg LPS at 12 h. The insets in d, h, and i show a higher magnification of a representative area from each field. Arrows indicate PlGF signal. Bar: 50 mum; (insets) 25 mum. (D, a) Survival curves for male PLGF+/+ (wild-type, WT) or PLGF-/- (knockout, KO) mice injected i.p. with 18 mg/kg LPS. (b) Survival curves for female PLGF+/+ (WT) or PLGF-/- (KO) mice injected i.p. with 18 mg/kg LPS. (c) Survival curves for wild-type male mice pretreated with anti-PlGF antibody (PlGF ab) or IgG (CTL ab) and injected i.p. with 18 mg/kg LPS. (d) Survival curves for male PLGF+/+ (WT) or PLGF-/- (KO) mice subjected to CLP. (e) Survival curves for female PLGF+/+ (WT) or PLGF-/- (KO) mice subjected to CLP. (f) Survival curves for wild-type male mice pretreated with anti-PlGF antibody (PlGF ab) or IgG (CTL ab) and subjected to CLP. Data in A and B are expressed as means + SD of at least three independent experiments. *, P < 0.05; **, P < 0.01; and ***, P < 0.0001 compared with no treatment (0 h time point).
###end p 10
###begin title 11
PlGF deficiency is associated with increased sepsis mortality
###end title 11
###begin p 12
###xml 102 105 102 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 319 322 319 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 368 371 368 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 427 430 427 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 471 474 471 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 487 495 487 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 D</xref>
###xml 1034 1042 1034 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 1287 1295 1287 1295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 D</xref>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
###xml 564 568 <span type="species:ncbi:10090">mice</span>
###xml 722 726 <span type="species:ncbi:10090">mice</span>
###xml 835 839 <span type="species:ncbi:10090">mice</span>
###xml 1066 1070 <span type="species:ncbi:10090">mice</span>
###xml 1169 1173 <span type="species:ncbi:10090">mice</span>
###xml 1224 1228 <span type="species:ncbi:10090">mice</span>
###xml 1338 1342 <span type="species:ncbi:10090">mice</span>
We next wished to determine whether PlGF contributes to sepsis outcome. To that end, 10-12-wk-old PlGF-/- mice or wild-type littermates were administered 18 mg/kg LPS or subjected to CLP. PlGF deficiency was associated with significantly lower survival rate in both the endotoxemia model (wild-type male, 62.5% vs. PlGF-/- male, 11.8%; wild-type female, 56.3% vs. PlGF-/- female, 12.5%) and in CLP (wild-type male, 50% vs. PlGF-/- male, 0%; wild-type female, 50% vs. PlGF-/- female, 0%; Fig. 1 D). The differences in survival between wild-type male and female FVB mice were not statistically significant. Interestingly, the increased mortality associated with the genetic deficiency of PlGF was less pronounced in younger mice (6 wk old; unpublished data). To test for the effect of acute PlGF down-regulation in the adult animal, FVB mice were administered 1 mg of neutralizing monoclonal anti-PlGF antibody (clone 5D11D4) i.p. 20 h before initiation of sepsis. In these experiments, PlGF levels in the plasma were undetectable (see Fig. 2 A). In 10-12-wk-old male mice, anti-PlGF antibody-mediated depletion of PlGF resulted in reduced sepsis survival in LPS-treated mice (control IgG, 62.5% vs. PlGF antibody, 12.5%) and mice subjected to CLP (control IgG, 50% vs. PlGF antibody, 0%; Fig. 1 D). Similar results were obtained in female mice and in younger animals (6 wk old; unpublished data). Thus, PlGF has a protective role in sepsis.
###end p 12
###begin title 13
PlGF deficiency is associated with increased VEGF levels in sepsis
###end title 13
###begin p 14
###xml 151 152 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 297 303 297 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 377 380 377 380 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 416 433 416 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A, a and e</xref>
###xml 469 472 469 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 599 616 599 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A, b and d</xref>
###xml 753 759 753 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 892 909 892 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A, f and h</xref>
###xml 1001 1018 1001 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A, c and g</xref>
###xml 1252 1260 1252 1260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 1297 1300 1297 1300 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
###xml 265 269 <span type="species:ncbi:10090">mice</span>
###xml 381 385 <span type="species:ncbi:10090">mice</span>
###xml 473 477 <span type="species:ncbi:10090">mice</span>
###xml 1034 1038 <span type="species:ncbi:10090">mice</span>
###xml 1287 1291 <span type="species:ncbi:10090">mice</span>
###xml 1301 1305 <span type="species:ncbi:10090">mice</span>
We previously demonstrated that endotoxemia in mice is associated with increased circulating levels of VEGF, sFlt-1, and the inflammatory marker IL-6 (7). In this study, there were no differences in baseline plasma levels of VEGF, sFlt-1, or IL-6 in PlGF-deficient mice versus wild-type controls (Fig. 2). As expected, PlGF levels were undetectable under all conditions in PlGF-/- mice and antibody-treated animals (Fig. 2 A, a and e). In response to 16 mg/kg LPS, PlGF-/- mice demonstrated significantly higher plasma levels of VEGF (2.6-fold) and IL-6 (2.4-fold) compared with wild-type controls (Fig. 2 A, b and d). The dose of 16 mg/kg LPS was chosen for these and subsequent morbidity experiments because 18 mg/kg LPS led to nearly 100% mortality (Fig. 1). A similar effect was observed in PlGF antibody-treated animals compared with IgG-injected controls (VEGF, 3-fold; IL-6, 1.7-fold; Fig. 2 A, f and h). In contrast, PlGF deficiency did not influence endotoxemia-mediated induction of sFlt-1 (Fig. 2 A, c and g). In wild-type mice, endotoxemia was associated with reduced VEGF protein levels in the lung at 6 h, and in the lung and brain at 24 h, and with increased VEGF protein levels in the liver and kidney at 6 h and in the spleen at 24 h (Fig. 2 B). Compared with wild-type mice, PlGF-/- mice demonstrated significantly higher levels of VEGF protein and mRNA in the liver at 24 h. Thus, PlGF deficiency results in increased circulating levels of VEGF and sustained induction of VEGF expression in the liver.
###end p 14
###begin p 15
###xml 0 94 0 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of PlGF deficiency on tissue and/or circulating levels of PlGF, VEGF, sFlt-1, and IL-6.</bold>
###xml 108 111 108 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 124 127 124 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 465 468 465 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 481 484 481 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 138 142 <span type="species:ncbi:10090">mice</span>
###xml 345 349 <span type="species:ncbi:10090">mice</span>
###xml 490 494 <span type="species:ncbi:10090">mice</span>
###xml 544 549 <span type="species:ncbi:10090">Mouse</span>
###xml 865 869 <span type="species:ncbi:10090">mice</span>
Effect of PlGF deficiency on tissue and/or circulating levels of PlGF, VEGF, sFlt-1, and IL-6. (A, a-d) PLGF+/+ (WT) or PLGF-/- (KO) male mice were injected i.p. with or without 16 mg/kg LPS. Blood samples were taken 24 h later and assayed for plasma levels of free PlGF, free VEGF, sFlt-1, and IL-6. (e-h) Same as in a-d, except that wild-type mice were pretreated with anti-PlGF antibody (Pab) or IgG (CTL) and injected i.p. with or without 16 mg/kg LPS. (B) PLGF+/+ (WT) or PLGF-/- male mice were injected i.p. with or without 16 mg/kg LPS. Mouse organs were assayed for VEGF protein levels by ELISA at the time points indicated. Data are expressed as means + SD of three independent experiments. *, P < 0.05; **, P < 0.01; and ***, P < 0.0001 compared with the respective untreated controls (and where indicated between LPS-treated PlGF-deficient and wild-type mice).
###end p 15
###begin title 16
PlGF deficiency is associated with increased endotoxemia-mediated cardiac dysfunction and barrier dysfunction
###end title 16
###begin p 17
###xml 38 39 38 39 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 221 229 221 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 304 307 304 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 314 325 314 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A, b</xref>
###xml 377 388 377 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A, d</xref>
###xml 460 471 460 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A, c</xref>
###xml 611 614 611 614 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 699 710 699 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B, a</xref>
###xml 827 838 827 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B, b</xref>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
###xml 308 312 <span type="species:ncbi:10090">mice</span>
###xml 344 348 <span type="species:ncbi:10090">mice</span>
###xml 579 583 <span type="species:ncbi:10090">mice</span>
###xml 615 619 <span type="species:ncbi:10090">mice</span>
Consistent with our previous results (7), systemic administration of LPS or CLP in mice resulted in marked depression of cardiac function, as indicated by reduced fractional shortening and heart rate on echocardiography (Fig. 3 A). The effect of endotoxin on fractional shortening was accentuated in PlGF-/- mice (Fig. 3 A, b) and in wild-type mice administered PlGF antibody (Fig. 3 A, d). Endotoxemic-associated bradycardia was accentuated by PlGF antibody (Fig. 3 A, c). PlGF deficiency was also associated with an accentuation of barrier dysfunction. Compared with wild-type mice, LPS administration in PlGF-/- mice resulted in increased extravasation of Evans blue dye in the liver and spleen (Fig. 3 B, a). Antibody-mediated depletion of PlGF resulted in increased extravasation occurring in the lung, liver, and kidney (Fig. 3 B, b). Collectively, these findings suggest that PlGF deficiency is associated with impaired cardiac function and organ-specific accentuation of vascular permeability during sepsis.
###end p 17
###begin p 18
###xml 0 104 0 104 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of PlGF deficiency on cardiac function and vascular permeability in a mouse model of endotoxemia.</bold>
###xml 122 125 122 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 138 141 138 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 534 537 534 537 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 553 556 553 556 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 77 82 <span type="species:ncbi:10090">mouse</span>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
###xml 411 415 <span type="species:ncbi:10090">mice</span>
###xml 570 574 <span type="species:ncbi:10090">mice</span>
###xml 716 720 <span type="species:ncbi:10090">mice</span>
###xml 973 977 <span type="species:ncbi:10090">mice</span>
###xml 1302 1306 <span type="species:ncbi:10090">mice</span>
Effect of PlGF deficiency on cardiac function and vascular permeability in a mouse model of endotoxemia. (A, a and b) PLGF+/+ (WT) or PLGF-/- (KO) male mice were injected i.p. with or without 16 mg/kg LPS and were subjected to echocardiogram and electrocardiogram 24 h later. Shown are quantitative analyses for heart rate (HR) and fractional shortening (FS). (c and d) Same as in a and b except that wild-type mice were pretreated with anti-PlGF antibody (Pab) or IgG (CTL) and injected i.p. with or without 16 mg/kg LPS. (B, a) PLGF+/+ (WT, W) or PLGF-/- (KO, K) male mice were injected i.p. with or without 16 mg/kg LPS. 24 h later, the animals were injected i.v. with 0.1 ml 1% Evans blue dye. After 40 min, the mice were perfused, and the brain, lung, heart, liver, kidney, and spleen were harvested and incubated in formamide for 3 d to elute Evans blue dye. Shown is the quantitation of Evans blue extravasation (OD = 620 nm). (b) Same as in a except that wild-type mice were pretreated with anti-PlGF antibody (PlGF ab, P) or IgG (CTL IgG, C) and injected i.p. with or without 16 mg/kg LPS. Data are expressed as means + SD of three independent experiments. *, P < 0.05; and **, P < 0.01 compared with the respective untreated controls (and where indicated between PlGF-deficient and wild-type mice).
###end p 18
###begin title 19
PlGF deficiency results in altered endotoxemia-mediated expression of inflammatory and coagulation mediators
###end title 19
###begin p 20
###xml 50 53 50 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 176 182 176 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4</xref>
###xml 1038 1046 1038 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 54 58 <span type="species:ncbi:10090">mice</span>
Compared with wild-type controls, endotoxemic PlGF-/- mice demonstrated significant vascular bed-specific changes in the expression of inflammatory and procoagulant molecules (Fig. 4; and Fig. S1, available at ). Specifically, PlGF deficiency resulted in increased expression of intercellular adhesion molecule (ICAM)-1 in the heart (1.9-fold), lung (1.7-fold), liver (6.5-fold), kidney (2.7-fold), and spleen (1.4-fold); increased expression of vascular cell adhesion molecule (VCAM)-1 in the liver (2.9-fold); increased E-selectin expression in the heart (2.8-fold) and liver (6.9-fold) but decreased E-selectin expression in the lung (0.5-fold); increased P-selectin expression in the lung (1.5-fold) and liver (3.7-fold); increased cyclooxygenase (COX)-2 expression in the heart (2.9-fold), liver (47.5-fold), kidney (5.7-fold), and spleen (4.5-fold); and increased plasminogen activator inhibitor (PAI)-1 in the liver (5.3-fold) and decreased PAI-1 in the heart (0.3-fold), brain (0.3-fold), kidney (0.6-fold), and spleen (0.3-fold; Fig. 4 A and Fig. S1).
###end p 20
###begin p 21
###xml 0 127 0 127 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of PlGF deficiency on tissue mRNA/protein levels of inflammatory and hemostatic markers in a mouse model of endotoxemia.</bold>
###xml 132 135 132 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 148 151 148 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 305 306 305 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 805 808 805 808 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 100 105 <span type="species:ncbi:10090">mouse</span>
###xml 162 166 <span type="species:ncbi:10090">mice</span>
###xml 625 629 <span type="species:ncbi:10090">mice</span>
###xml 729 733 <span type="species:ncbi:10090">mice</span>
###xml 809 813 <span type="species:ncbi:10090">mice</span>
Effect of PlGF deficiency on tissue mRNA/protein levels of inflammatory and hemostatic markers in a mouse model of endotoxemia. PLGF+/+ (WT) or PLGF-/- (KO) male mice were injected i.p. with or without 16 mg/kg LPS. (A) Shown are the results of quantitative real-time PCR analyses (mRNA copy number per 106 copies of 18S) of ICAM-1, VCAM-1, E-selectin, P-selectin, COX-2, and PAI-1 in the heart, lung and liver at 24 h. Data are expressed as means + SD of three independent experiments. *, P < 0.05; **, P < 0.01; and ***, P < 0.0001 compared with untreated controls (and where indicated between PlGF-deficient and wild-type mice). (B) Double immunofluorescence staining for activation markers and CD31 in the liver of wild-type mice treated in the absence (WT) or presence of 16 mg/kg LPS (WT/L) and PlGF-/- mice treated with 16 mg/kg LPS (PKO/L) at 24 h. (a) ICAM-1 (green) and CD31 (red). (b) VCAM-1 (green) and CD31 (red). (c) E-selectin (green) and CD31 (red). (d) P-selectin (green) and CD31 (red). (e) COX-2 (red) and CD31 (green). (f) PAI-1 (red) and CD31 (green). Bars: 132 mum; (insets) 42 mum.
###end p 21
###begin p 22
###xml 285 302 285 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B, a and d</xref>
###xml 354 365 354 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B, f</xref>
###xml 453 464 453 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B, b</xref>
###xml 529 540 529 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B, c</xref>
###xml 596 607 596 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B, e</xref>
###xml 631 634 631 634 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 738 755 738 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B, a and d</xref>
###xml 827 838 827 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B, b</xref>
###xml 933 950 933 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B, c and f</xref>
###xml 1011 1022 1011 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B, e</xref>
###xml 635 639 <span type="species:ncbi:10090">mice</span>
Immunofluorescent studies were used to determine the localization of the mediators described in the previous paragraph in the liver, heart, and lung. In the wild-type liver, LPS resulted in increased expression of ICAM-1 and P-selectin in endothelial cells of the sinusoids and veins (Fig. 4 B, a and d), and PAI-1 in sinusoidal endothelial cells alone (Fig. 4 B, f). LPS appeared to result in a slight induction of VCAM-1 in venular endothelial cells (Fig. 4 B, b) and of E-selectin in sinusoidal and venular endothelial cells (Fig. 4 B, c). COX-2 was induced in occasional CD31-negative cells (Fig. 4 B, e). LPS injection of PlGF-/- mice resulted in the further induction of ICAM-1 and P-selectin in sinusoidal and venular endothelium (Fig. 4 B, a and d), increased expression of VCAM-1 in both endothelial cell populations (Fig. 4 B, b), increased expression of E-selectin and PAI-1, particularly in sinusoidal endothelial cells (Fig. 4 B, c and f), and increased expression of COX-2 in CD31-negative cells (Fig. 4 B, e). Larger images of the liver data are shown in Fig. S2 (A and B; available at ).
###end p 22
###begin p 23
###xml 236 239 236 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 381 384 381 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 38 42 <span type="species:ncbi:10090">mice</span>
###xml 240 244 <span type="species:ncbi:10090">mice</span>
###xml 385 389 <span type="species:ncbi:10090">mice</span>
In the heart of LPS-treated wild-type mice, ICAM-1, VCAM-1, E-selectin, and P-selectin were induced in capillary and venular endothelium, whereas COX-2 and PAI-1 were slightly increased in CD31-negative cells (Fig. S2, C and D). In PlGF-/- mice, LPS administration resulted in increased endothelial expression of ICAM-1 and E-selectin but not VCAM-1 or P-selectin. Endotoxemic PlGF-/- mice demonstrated increased expression of COX-2 and decreased expression of PAI-1 in CD31-negative endothelial cells.
###end p 23
###begin p 24
###xml 426 429 426 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 40 44 <span type="species:ncbi:10090">mice</span>
###xml 430 434 <span type="species:ncbi:10090">mice</span>
In the lung, LPS injection of wild-type mice resulted in increased expression of ICAM-1 and P-selectin in venular and capillary endothelium and possibly in parenchymal cells (Fig. S2, E and F). VCAM-1 and E-selectin were increased primarily in venular endothelium. COX-2 was increased in CD31-negative cells on the luminal side of venular endothelium. PAI-1 was slightly induced, primarily in venous endothelial cells. In PlGF-/- mice, LPS resulted in a further increase in the expression of ICAM-1 and P-selectin but no demonstrable change in VCAM-1, E-selectin, or PAI-1. In addition, COX-2 was up-regulated in CD31-negative cells in the lumen of veins. Together with the real-time PCR data, these findings demonstrate that PlGF deficiency results in vascular bed-specific changes in the expression of inflammatory and coagulation markers, with the most widespread changes occurring in the liver.
###end p 24
###begin title 25
PlGF deficiency results in liver dysfunction and leukocyte infiltration
###end title 25
###begin p 26
###xml 451 454 451 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 520 523 518 521 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 549 557 545 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 667 670 663 666 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 698 706 694 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 B</xref>
###xml 828 831 824 827 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 874 882 870 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 1005 1008 1001 1004 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 868 872 <span type="species:ncbi:10090">mice</span>
###xml 1009 1013 <span type="species:ncbi:10090">mice</span>
The results described in the previous three sections suggest that PlGF deficiency is associated with disproportionate endotoxemia-mediated changes in the liver, including sustained elevation of VEGF, increased permeability, and higher expression of activation markers. Based on these findings, we wished to further explore the effect of PlGF deficiency on the liver phenotype. Alanine aminotransferase, a measure of liver damage, was increased in PlGF-/- versus wild-type controls (wild-type, 63.3 +/- 35.1 U/liter; PlGF-/-, 223.3 +/- 92.9 U/liter; Fig. 5 A). Moreover, endotoxemia resulted in significantly greater myeloperoxidase (MPO) activity in the liver of PlGF-/- versus wild-type controls (Fig. 5 B). Consistent with these latter findings, CD45 staining demonstrated increased leukocyte infiltration in the liver of PlGF-/- compared with wild-type endotoxemic mice (Fig. 5 C). In contrast to the findings in the liver, MPO activity in the lung did not differ between endotoxemia wild-type and PlGF-/- mice (unpublished data).
###end p 26
###begin p 27
###xml 0 77 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of PlGF deficiency on liver phenotype in a mouse model of endotoxemia.</bold>
###xml 82 85 82 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 98 101 98 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 50 55 <span type="species:ncbi:10090">mouse</span>
###xml 112 116 <span type="species:ncbi:10090">mice</span>
###xml 604 608 <span type="species:ncbi:10090">mice</span>
Effect of PlGF deficiency on liver phenotype in a mouse model of endotoxemia. PLGF+/+ (WT) or PLGF-/- (KO) male mice were injected i.p. with or without 16 mg/kg LPS. (A) Blood samples were taken at 24 h and assayed for plasma levels of alanine aminotransferase (ALT). (B) The liver was removed at 24 h and assayed for MPO activity. (C) The liver was removed at 24 h and stained for CD45. Data in A and B are expressed as means + SD of three independent experiments. *, P < 0.05; **, P < 0.01; and ***, P < 0.0001 compared with untreated controls (and where indicated between PlGF-deficient and wild-type mice. Bar, 50 mum.
###end p 27
###begin title 28
###xml 47 51 <span type="species:ncbi:10090">mice</span>
Excess mortality in endotoxemic PlGF-deficient mice is accentuated by overexpression of VEGF and rescued by overexpression of sFlt-1
###end title 28
###begin p 29
###xml 43 46 43 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 91 99 91 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 541 544 539 542 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 560 568 558 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 B</xref>
###xml 695 698 691 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 755 758 751 754 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 767 775 763 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 B</xref>
###xml 885 893 881 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 C</xref>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
###xml 187 191 <span type="species:ncbi:10090">mice</span>
###xml 397 401 <span type="species:ncbi:10090">mice</span>
###xml 545 549 <span type="species:ncbi:10090">mice</span>
###xml 1038 1042 <span type="species:ncbi:10090">mice</span>
The increased mortality in endotoxemic PlGF-/- mice was rescued by overexpression of PlGF (Fig. 6 A). However, the elevated circulating levels of PlGF in the PlGF-adenovirus (Ad)-treated mice (5,823.4 +/- 833.6 pg/ml) did not confer a survival advantage over GFP-Ad (control)-injected wild-type animals. To determine whether PlGF deficiency rendered animals more sensitive to the effects of VEGF, mice were injected with control virus or VEGF-Ad and administered small doses of LPS (14 mg/kg). At the latter dose, 93.8% of wild-type and PlGF-/- mice survived (Fig. 6 B). However, overexpression of VEGF (plasma levels, 4,204.5 +/- 901.8 pg/ml) resulted in a marked increased in mortality in PlGF-/- compared with wild-type animals (wild-type, 50% vs. PlGF-/-, 100%) (Fig. 6 B). Finally, the increased mortality associated with PlGF deficiency was reversed by overexpression of sFlt-1 (Fig. 6 C). Collectively, these results suggest that elevated VEGF levels are both sufficient and necessary to promote sepsis mortality in PlGF-deficient mice.
###end p 29
###begin p 30
###xml 0 54 0 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Additional survival studies in mouse models of sepsis.</bold>
###xml 64 67 64 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 80 83 80 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 31 36 <span type="species:ncbi:10090">mouse</span>
###xml 84 88 <span type="species:ncbi:10090">mice</span>
Additional survival studies in mouse models of sepsis. Male PLGF+/+ (WT) or PLGF-/- mice were injected with Ad overexpressing GFP (GFP-ad) or PlGF (PlGF-ad; A), VEGF (VEGF-ad; B), or sFlt-1 (sFlt-ad; C). 3 d later, the animals were administered saline (control) or LPS i.p. and monitored for survival.
###end p 30
###begin title 31
DISCUSSION
###end title 31
###begin p 32
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 707 709 707 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 729 731 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 755 757 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 779 781 779 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 878 880 878 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 882 884 882 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 886 888 886 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 889 891 889 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
Compared with our understanding of VEGF, little is known about the function of PlGF. PlGF is thought to bind to VEGFR1/Flt-1 and the coreceptors neuropilin-1 and -2. The interaction between PlGF and VEGFR1/Flt-1 has been shown both to trigger downstream signaling and to enhance VEGF signaling via VEGFR2/Flk-1 (for review see reference 35). Although PlGF is not required for developmental angiogenesis, it appears to play an important role in postnatal angiogenesis, arteriogenesis, and vasculogenesis (21). In addition, increasing evidence points to a proinflammatory effect of PlGF. Most notably, PlGF-mediated induction of monocyte migration and activation has been shown to contribute to tumor growth (26), atherosclerosis (27), sickle cell disease (25), and wound healing (26). In addition, PlGF has been causally linked to vascular permeability and plasma extravasation (21, 23, 28-31).
###end p 32
###begin p 33
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 471 473 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 475 477 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 632 633 632 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 814 819 <span type="species:ncbi:10090">mouse</span>
From a mechanistic standpoint, it has been proposed that PlGF displaces VEGF from VEGFR1/Flt-1, thus promoting VEGF-VEGFR2/Flk-1 interactions (36). Moreover, PlGF-mediated activation of VEGFR1/Flt-1 may lead to the transactivation of VEGFR2/Flk-1, further enhancing the response to VEGF (37). Previous studies have revealed that PlGF up-regulates the expression of VEGF by periendothelial fibroblasts, smooth muscle cells, or inflammatory cells in wound or tumor stroma (38, 39). Together with our recent observations that sepsis is associated with elevated levels of VEGF and PlGF, and that VEGF plays a pathogenic role in sepsis (7), these data led us to hypothesize that elevated levels of PlGF would accentuate sepsis morbidity and mortality. On the contrary, we found that PlGF plays a net protective role in mouse models of sepsis.
###end p 33
###begin p 34
###xml 276 279 276 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">41</xref>
###xml 614 616 614 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">41</xref>
###xml 763 765 763 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">42</xref>
###xml 178 182 <span type="species:ncbi:10090">mice</span>
###xml 280 284 <span type="species:ncbi:10090">mice</span>
A clue to the mechanism by which PlGF deficiency causes increased morbidity and mortality was found in our discovery of elevated circulating VEGF levels in septic PlGF-deficient mice. Moreover, Ad-mediated expression of sFlt-1 reversed the excess mortality in LPS-treated PlGF-/- mice. Thus, the increased mortality associated with PlGF deficiency is attributed, at least in part, to exaggerated VEGF levels. Previous studies have demonstrated that PlGF and VEGF, when produced by the same cell, may form PlGF/VEGF heterodimers (40, 41). PlGF/VEGF heterodimers, in turn, have been shown to inhibit VEGF signaling (41). In response to LPS, we found the majority of PlGF up-regulation in perivascular cells. Perivascular cells have also been shown to express VEGF (42). Thus, it is tempting to speculate that the loss of PlGF yields not only elevated levels of free VEGF but also increased homodimerization and, thus, bioactivity of VEGF.
###end p 34
###begin p 35
###xml 308 310 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">43</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 474 476 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 718 720 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 831 833 831 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 825 829 <span type="species:ncbi:10090">mice</span>
The prevailing view in the literature is that PlGF functions as a proinflammatory and permeability-enhancing cytokine. However, the results of the present study indicate that these effects of PlGF are highly context dependent. For example, although PlGF induces vascular permeability in several skin models (30, 31), it promotes barrier function in sepsis. PlGF has been shown to promote monocyte infiltration in ischemic tissues (43), tumors (26), atherosclerotic plaques (27), and bone fractures (24). However, as we have demonstrated in this paper, PlGF inhibits leukocyte accumulation in the liver of septic animals. Previous studies have shown that PlGF up-regulates VEGF expression in wound or tumor stroma (38, 39). Moreover, neutralizing anti-PlGF antibody failed to induce VEGF levels in the plasma in tumor-bearing mice (26). In contrast, PlGF deficiency is clearly associated with increased VEGF levels in sepsis. Additional studies will be needed to determine the precise mechanism by which PlGF signaling limits VEGF release and signaling under these conditions.
###end p 35
###begin p 36
###xml 271 279 <span type="species:ncbi:9606">patients</span>
In summary, our findings suggest that the up-regulation of PlGF represents an adaptive host response to infection. As anti-PlGF therapies become more widespread for the treatment of such conditions as cancer and atherosclerosis, it will be important to carefully monitor patients for the development of infections and systemic inflammatory response syndrome.
###end p 36
###begin title 37
MATERIALS AND METHODS
###end title 37
###begin title 38
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice.
###end title 38
###begin p 39
###xml 278 279 278 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 379 383 <span type="species:ncbi:10090">mice</span>
Mouse models of endotoxemia and CLP; measurement of IL-6, VEGF, sFlt-1, and PlGF in plasma; Ad-mediated overexpression of sFlt-1, VEGF, and PlGF; cardiac physiological studies; permeability assays; tissue RNA isolation; and real-time PCR were performed as previously described (7). Unless otherwise indicated in the figures, all experiments were performed using 10-12-wk-old FVB mice. All animal studies were approved by the Beth Israel Deaconess Medical Center Institutional Animal Care and Use Committee.
###end p 39
###begin title 40
Survival studies.
###end title 40
###begin p 41
Survival studies were performed using endotoxemia and CLP models. Survival was assessed at 24, 48, 72, and 96 h after 14-18 mg/kg body weight LPS injection or CLP. In studies involving adenoviral administration, the virus was injected 3 d before LPS administration. The same lot of LPS was used throughout the study. An LPS dose-response curve is shown in Fig. S3 (available at ).
###end p 41
###begin title 42
Antibody administration.
###end title 42
###begin p 43
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
###xml 78 83 <span type="species:ncbi:10090">mouse</span>
20 h before LPS or CLP administration, mice were injected i.p. with 1 mg anti-mouse PlGF-2 antibody (PL5D11D4) or the same dose of control antibody (1C8). The efficacy of this antibody has been previously reported (26).
###end p 43
###begin title 44
Immunohistochemistry.
###end title 44
###begin p 45
###xml 99 104 <span type="species:ncbi:10090">mouse</span>
###xml 123 126 <span type="species:ncbi:10116">rat</span>
###xml 143 148 <span type="species:ncbi:10090">mouse</span>
###xml 183 186 <span type="species:ncbi:10116">rat</span>
###xml 203 208 <span type="species:ncbi:10090">mouse</span>
###xml 247 250 <span type="species:ncbi:10116">rat</span>
###xml 267 272 <span type="species:ncbi:10090">mouse</span>
###xml 306 312 <span type="species:ncbi:9986">rabbit</span>
###xml 329 334 <span type="species:ncbi:10090">mouse</span>
###xml 373 379 <span type="species:ncbi:9986">rabbit</span>
###xml 396 401 <span type="species:ncbi:10090">mouse</span>
###xml 531 534 <span type="species:ncbi:10116">rat</span>
###xml 551 556 <span type="species:ncbi:10090">mouse</span>
###xml 634 638 <span type="species:ncbi:9925">goat</span>
###xml 655 660 <span type="species:ncbi:10090">mouse</span>
###xml 776 779 <span type="species:ncbi:10116">rat</span>
###xml 807 810 <span type="species:ncbi:10116">rat</span>
###xml 864 868 <span type="species:ncbi:9925">goat</span>
###xml 925 931 <span type="species:ncbi:9986">rabbit</span>
Immunohistochemistry was performed using the following primary antibodies: hamster monoclonal anti-mouse ICAM-1 (Serotec), rat monoclonal anti-mouse VCAM-1 antibody (BD Biosciences), rat monoclonal anti-mouse E-selectin antibody (BD Biosciences), rat monoclonal anti-mouse P-selectin antibody (Millipore), rabbit polyclonal anti-mouse COX-2 antibody (Cayman Chemical), and rabbit polyclonal anti-mouse PAI-1 antibody (Innovative Research Inc.). For double immunofluorescence, ICAM-1, COX-2, and PAI-1 antibodies were combined with rat monoclonal anti-mouse CD31 (BD Biosciences); VCAM-1, E-selectin, and P-selectin were combined with goat polyclonal anti-mouse CD31 antibody (Santa Cruz Biotechnology, Inc.. Secondary antibodies included anti-hamster IgG-FITC (Serotec), anti-rat IgG-Cy3 (Invitrogen), anti-rat IgG-FITC (Jackson ImmunoResearch Laboratories), anti-goat IgG-Cy3 (Jackson ImmunoResearch Laboratories), and anti-rabbit IgG-Cy3 (Invitrogen). The combinations of primary and secondary antibodies are detailed in Table S1 (available at ). As a negative control, slides were incubated with secondary antibody alone. Representative images were captured by using a confocal microscope (LSM 510 Meta; Carl Zeiss, Inc.).
###end p 45
###begin p 46
###xml 25 30 <span type="species:ncbi:10090">mouse</span>
###xml 91 95 <span type="species:ncbi:9925">goat</span>
###xml 101 106 <span type="species:ncbi:10090">mouse</span>
###xml 507 511 <span type="species:ncbi:9925">goat</span>
Immunohistochemistry for mouse PlGF-2 was performed on 5-mum fixed frozen sections using a goat anti-mouse PlGF antibody (Santa Cruz Biotechnology, Inc.). In brief, after tissue fixation with 4% paraformaldehyde for 1 h, tissues were incubated in PBS for 1 h, followed by 20% sucrose for 4 h before embedding in optimal cutting temperature compound. Cryosections were pretreated with heat (antigen retrieval procedure) in 10 mM citrate buffer (pH 6.4) and incubated with primary antibody. Biotinylated anti-goat IgG and the Elite vectastain ABC kit (Vector Laboratories) were used to detect PlGF protein expression. Biotin blocker (Dako) was used to block endogenous biotin.
###end p 46
###begin title 47
In situ hybridization for PlGF.
###end title 47
###begin p 48
###xml 61 63 61 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">44</xref>
###xml 100 105 <span type="species:ncbi:10090">mouse</span>
###xml 229 234 <span type="species:ncbi:10090">mouse</span>
###xml 440 445 <span type="species:ncbi:10090">mouse</span>
In situ hybridization was performed as previously described (44). For in situ hybridization probes, mouse PlGF-2 cDNA (472 bp, nucleotides 17-489; available from GenBank/EMBL/DDBJ under accession no. ) was amplified by RT-PCR of mouse heart RNA and subcloned into the pcDNA3 (+) vector (Invitrogen). Digoxigenin-labeled antisense and sense RNA probes (Roche) were prepared by in vitro transcription with T7 RNA polymerase, using linearized mouse PlGF-2 pcDNA3 (+) as a template.
###end p 48
###begin title 49
MPO activity.
###end title 49
###begin p 50
###xml 104 105 104 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 429 430 423 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
Snap-frozen liver samples were homogenized in 20 mM phosphate buffer (pH 7.4) and centrifuged at 10,000 g for 10 min at 4degreesC, and the resulting pellet was resuspended in 50 mM phosphate buffer (pH 6) containing 0.5% hexadecyltrimethylammonium bromide (Sigma-Aldrich). The suspension was resubjected to four cycles of freezing and thawing and disrupted further by sonication (40 s). The sample was then centrifuged at 10,000 g for 5 min at 4degreesC, and the supernatant was used for the MPO activity assay. The MPO assay was performed using the NWLSS Myeloperoxidase Activity Assay kit (Northwest), as instructed by the manufacturer. The absorbance was corrected for the DNA content of the tissue sample and expressed as the percent increase over those of wild-type liver tissue.
###end p 50
###begin title 51
Statistical analyses.
###end title 51
###begin p 52
###xml 239 243 <span type="species:ncbi:10090">mice</span>
###xml 302 306 <span type="species:ncbi:10090">mice</span>
A two-way analysis of variance followed by a Fisher's exact test was used to compare morbidity measurements, including cytokine levels, vascular leakage, cardiac physiology, MPO activity, and gene expression in wild-type and PlGF knockout mice, and in control IgG or PlGF neutralizing antibody-treated mice with or without LPS administration. The Wilcoxon log-rank test was used for survival studies.
###end p 52
###begin title 53
Online supplemental material.
###end title 53
###begin p 54
###xml 520 528 520 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 176 180 <span type="species:ncbi:10090">mice</span>
###xml 404 408 <span type="species:ncbi:10090">mice</span>
###xml 593 597 <span type="species:ncbi:10090">mice</span>
Fig. S1 shows the effect of PlGF deficiency on mRNA levels of inflammatory and hemostatic markers in the brain (a-f), kidney (g-l), and spleen (m-r) of control and endotoxemic mice, as measured by real-time PCR. Fig. S2 shows the effect of PlGF deficiency on protein expression of inflammatory and hemostatic markers in the liver (A and B), heart (C and D), and lung (E and F) of control and endotoxemia mice, as measured by double immunofluorescence. The images of the liver represent larger versions of those shown in Fig. 4 B. Fig. S3 shows an LPS dose-response survival study in wild-type mice. Table S1 shows antibodies used in immunohistochemistry. Online supplemental material is available at .
###end p 54
###begin title 55
Supplementary Material
###end title 55
###begin title 56
[Supplemental Material Index]
###end title 56
###begin p 57
We thank Pat D'Amore and Richard Mulligan for help with the generation of Ad's expressing PlGF, VEGF-A (isoform 120), and sFlt-1, respectively.
###end p 57
###begin p 58
Supported in part by National Institutes of Health grants HL076540, HL077348, and HL082927 (to W.C. Aird). S.A. Karumanchi is an investigator of the Howard Hughes Medical Institute.
###end p 58
###begin p 59
P. Carmeliet declares to be named as inventor on patent EP1297016 and pending foreign counterparts, claiming subject matter that partially covers the results described in this paper. This patent is outlicensed and entitles P. Carmeliet to receive royalty payments. The authors have no additional competing financial interests.
###end p 59

